Similarly, in a BRAFV600E melanoma model, treatment with vemurafenib was shown to upregulate EGFR expression to overcome the mitogen-activated protein kinase (MAPK) pathway inhibition in response to drug treatment. The gene discussed is EGFR; the disease is melanoma.